Axon expands in the US
pharmafile | March 4, 2010 | News story | Medical Communications | Axon, medical communications
Surrey, UK-based Axon Communications has appointed Mario Nacinovich as managing director of its new US operations.
Nacinovich will be based in New York and will report to Ralph Sutton, the healthcare consulting firm’s managing partner who is based in London.
Sutton said: “Expansion of our US operations and Mario’s arrival further strengthens our international capabilities and brings an added US dimension to Axon’s unique combined offering of public relations, medical communications, and clinical research consulting.
“We expect this office to go from strength to strength and, based on recent successes, are actively building the team to service existing and new clients.”
In its first few weeks of operation, the agency has already secured a client roster that includes major pharmaceutical and medical device manufacturers.
Prior to joining Axon, Nacinovich was VP of strategic planning and business development at Connecticut-based medical education firm QD Healthcare Group.
He has also previously held a number of senior positions including chief growth Officer for Caudex Medical, Co-chief executive and co-founder of Fission Communications, part of Regan Campbell Ward – McCann of McCann Healthcare Worldwide, and VP of Strategic Planning, Director of Business Development and VP of Ophthalmology at Ventiv Health.
Nacinovich began his career at Merck & Co, and served in various sales and marketing roles in the company’s US human health division.
Axon, which is part of the Montreal-headquartered National group of companies, provides medical communications, public relations and clinical research consulting services.
Related Content
Men’s health – a new report from the Department of Health and Social Care
The UK Department of Health and Social Care has published a new report entitled Men’s …
PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025
The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …
Axon seeks global partner after positive Phase 2 data for Alzheimer’s vaccine
Axon Neuroscience has announced data from its Phase 2 trial ADAMANT for the first-in-class vaccine …
